Intelligence

Healthcare

Regentis reports first-half 2026 results as GelrinC trial reaches 43 patients

Author:
FAQSIR News Desk
Last Updated:
Reading Time
4 min

Regentis Biomaterials Ltd. (NYSE American:RGNT) reported results for the six months ended June 30, 2026, alongside updates on its GelrinC regenerative medicine programme. The company said 43 of 80 patients had been recruited and treated in its U.S. pivotal Phase III trial and that it now expects full enrolment on or around the end of 2026, compared with its earlier expectation of the third quarter.

#U.S. GelrinC trial progresses

Regentis expanded its U.S. clinical network during the first half of 2026 and added orthopedic centres in the country. The company said the trial had completed over 50% enrolment, with 43 patients treated out of the planned 80.

Based on the current pace of enrolment, Regentis expects to complete enrolment of 80 patients on or around the end of this year. The company attributed the revised timing to the practical pace of site activation and patient recruitment in the U.S. and Europe. This remains a forward-looking expectation subject to the risks and uncertainties identified by Regentis.

#European preparations and manufacturing update

Regentis reported additions to its European clinical network in Italy, Germany, Serbia, Slovenia and Romania. GelrinC has CE Mark approval in the European Union, and the company said it continued preparations involving physician engagement and surgeon training through its European Centers of Excellence.

The company also reported a new solvent-free manufacturing process designed to increase GelrinC production yield by 400%. Regentis said it developed and filed patents covering the process and received regulatory approval from the European Notified Body in July. According to the company, the approval supports manufacturing scale-up for anticipated European commercial requirements and future market expansion; those anticipated activities remain subject to the stated risks and uncertainties.

Separately, the Japan Patent Office issued a Notice of Allowance for Regentis' application covering organic solvent-free compositions comprising protein-polymer conjugates and their uses. The application relates to the solvent-free technology used in GelrinC manufacturing.

#Clinical and product information

Regentis described GelrinC as a cell-free, off-the-shelf hydrogel implant intended for painful and debilitating focal articular knee cartilage injuries. The product has CE Mark approval in the European Union and is being evaluated in a pivotal U.S. Food and Drug Administration study.

The company also reported long-term MRI findings from GelrinC-treated patients at 24 months, describing layered cartilage architecture comparable to native hyaline cartilage. Peer-reviewed results from the GelrinC Phase II study, published in the journal Cartilage, used quantitative MOCART assessment and reported morphological cartilage repair through two years.

#First-half financial results

Research and development expenses were approximately $1.2 million for the six months ended June 30, 2026, compared with $180,000 for the same period in 2025. Regentis attributed the increase mainly to its pivotal clinical study, including personnel, production and material costs and outsourced services.

General and administrative expenses were approximately $1.2 million, compared with $259,000 in the first six months of 2025. The company said the change primarily reflected higher personnel-related expenses and costs associated with operating as a public company after its December 2025 initial public offering.

Operating loss was approximately $2.4 million, compared with $439,000 in the first six months of 2025. Net loss was approximately $2.6 million, or $0.44 per share, compared with approximately $3.2 million, or $1.17 per share, in the first six months of 2025. Regentis said the change in net loss primarily reflected a significant reduction in finance expenses, partly offset by higher research and development and general and administrative expenses.

#Financing and cash position

Regentis said it completed a private placement in June 2026 with aggregate gross proceeds of approximately $6.5 million. Cash and cash equivalents stood at approximately $9.0 million as of June 30, 2026, while net cash used in operating activities was approximately $2.8 million during the first six months of 2026.

The company also said that it had repaid its debt entirely as of June 30, 2026.

#Risks and uncertainties

Regentis cautioned that forward-looking statements are subject to substantial risks and uncertainties. The risks identified by the company include whether clinical trials demonstrate GelrinC's safety and efficacy, the timing and reporting of clinical data, obtaining and maintaining regulatory approval including FDA approval, market acceptance by medical professionals and third-party payors, competition from existing or future therapies, intellectual property protection, dependence on third parties, recruitment and retention of personnel, estimates of expenses, future revenue and capital requirements, additional financing needs, and the company's ability to repay loans and debts. Further terms and risk factors apply.

#Key Takeaways

  • Regentis reported that 43 of 80 patients had been recruited and treated in its U.S. pivotal Phase III GelrinC trial.
  • The company now expects full enrolment of 80 patients on or around the end of 2026, based on the current pace of enrolment.
  • European preparations continued, with new clinical sites, physician engagement and surgeon training under CE Mark approval.
  • A new manufacturing process was approved in July and is reported to increase production yield by 400%.
  • Regentis reported approximately $2.6 million in net loss, approximately $9.0 million in cash and cash equivalents, and approximately $6.5 million in private-placement gross proceeds for the period and related updates.

Original source: Read original article

Frequently Asked Questions

Regentis said it had recruited and treated 43 of 80 patients in its U.S. pivotal Phase III clinical trial and had expanded its U.S. clinical site network. The release also said the trial had completed over 50% enrolment. Based on the current pace of enrolment, the Company expects to complete full enrolment of 80 patients on or around the end of this year, compared with its previous expectation of the third quarter. Regentis attributed the timing to the practical pace of site activation and patient recruitment in the U.S. and Europe. The expectation is forward-looking and remains subject to the risks and uncertainties described in the release.
Regentis said it had added clinical sites in Italy, Germany, Serbia, Slovenia and Romania, and was preparing for GelrinC® commercialisation through physician engagement and surgeon training via its European Centers of Excellence. GelrinC® has CE Mark approval in the European Union. The release also stated that the Company was advancing its plans for European surgeon activities, which are identified as forward-looking and subject to risks and uncertainties.
Regentis said it had developed and filed patents for a new solvent-free manufacturing process that increases GelrinC® production yield by 400%. In July, the Company said it received regulatory approval for the process from the European Notified Body. Regentis also reported that the Japan Patent Office had issued a Notice of Allowance for a patent application covering organic solvent-free compositions comprising protein-polymer conjugates and their uses. The release described the manufacturing approval as supporting manufacturing scale-up for anticipated European commercial requirements and future market expansion; those anticipated requirements and expansion are forward-looking matters subject to the stated risks and uncertainties.
Research and development expenses were approximately $1.2 million, compared with $180,000 for the same period in 2025. General and administrative expenses were approximately $1.2 million, compared with $259,000 for the first six months of 2025. Operating loss was approximately $2.4 million, compared with $439,000 in the first six months of 2025. Net loss was approximately $2.6 million, or $0.44 per share, compared with approximately $3.2 million, or $1.17 per share, for the first six months of 2025. Regentis attributed the changes to factors including clinical study costs, higher personnel-related expenses, public-company costs and a reduction in finance expenses.
Regentis said it completed a private placement in June 2026 with aggregate gross proceeds of approximately $6.5 million. Cash and cash equivalents totalled approximately $9.0 million as of June 30, 2026, while net cash used in operating activities was approximately $2.8 million during the first six months of 2026. The Company also said that, as of June 30, 2026, it had repaid its debt entirely. The release identifies future financing requirements and the Company's ability to repay loans and debts among the risks and uncertainties affecting future results.
Regentis described GelrinC® as a cell-free, off-the-shelf hydrogel implant intended to treat painful and debilitating injuries to focal articular knee cartilage. It has CE Mark approval in the European Union and is being evaluated in a pivotal U.S. Food and Drug Administration study. The release said GelrinC® had been used in a single, 10-minute procedure and reported functional improvement for more than 5 years based on clinical study results to date. These descriptions and any future regulatory or commercial outcomes remain subject to clinical, safety, efficacy, market acceptance and regulatory risks identified by the Company.
Regentis Biomaterials Ltd. is identified in the release as listed on the NYSE American:RGNT. The Company highlighted risks including whether clinical trials demonstrate the safety and efficacy of GelrinC®, the timing and reporting of clinical data, obtaining and maintaining regulatory approval including FDA approval, market acceptance by the medical community and third-party payors, competition from existing or future therapies, intellectual property protection, dependence on third parties, the need for additional personnel, estimates of expenses, future revenue and capital requirements, and the need for additional financing. The release states that forward-looking statements are subject to substantial risks and uncertainties and that Regentis undertakes no duty to update them except as required under applicable law.